{
  "id": "60234dc61cb411341a000094",
  "type": "factoid",
  "question": "Which disease is treated with Emapalumab?",
  "ideal_answer": "Emapalumab is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3) that was approved by the Food and Drug Administration for primary hemophagocytic lymphohistiocytosis (HLH).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33484058",
    "http://www.ncbi.nlm.nih.gov/pubmed/31537529",
    "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
    "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
    "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
    "http://www.ncbi.nlm.nih.gov/pubmed/34096649",
    "http://www.ncbi.nlm.nih.gov/pubmed/32447592",
    "http://www.ncbi.nlm.nih.gov/pubmed/33424859",
    "http://www.ncbi.nlm.nih.gov/pubmed/30623346",
    "http://www.ncbi.nlm.nih.gov/pubmed/32817285"
  ],
  "snippets": [
    {
      "text": "All patients who received the complement blocker eculizumab in addition to the interferon gamma blocker emapalumab had complete resolution of their TMA and survived. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32447592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32374962",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients. FDA approval was based on the results of a phase II/III clinical trial evaluating the safety and efficacy of emapalumab in 34 pediatric patients with primary HLH, 27 of whom were refractory to current therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab, a fully human anti-IFN\u03b3 monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32817285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Available data support the use of emapalumab for treatment of pHLH patients with refractory, recurrent or progressive disease, or intolerance to conventional therapy, recently, leading to FDA approval of the drug for these indications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33424859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RT OPINION: Emapalumab is an effective treatment for HLH with a good safety profile. Its",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537529",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recently, the therapeutic potential of IFN-\u03b3 inhibition has been documented; emapalumab, an anti-IFN-\u03b3 monoclonal antibody, has been approved in the United States for treatment of primary HLH that is refractory, recurrent or progressive, or in patients with intolerance to conventional therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33484058",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab, a fully human anti-IFN\u03b3 monoclonal antibody, has been approved in the US as second-line treatment of primary hemophagocytic lymphohistiocytosis (HLH) patients and has shown promise in patients with graft failure (GF) requiring a second allogeneic hematopoietic stem cell transplantation (HSCT). The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32817285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "role. Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional ther",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. This",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab-Igsz (Gamifant) is a human monoclonal antibody directed against interferon-\u03b3 (IFN-\u03b3), and the first Food and Drug Administration (FDA)-approved therapy for primary hemophagocytic lymphohistiocytosis (HLH). HLH",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ", the therapeutic potential of IFN-\u03b3 inhibition has been documented; emapalumab, an anti-IFN-\u03b3 monoclonal antibody, has been approved in the United States for treatment of primary HLH that is refractory, recurrent or progressive, or in patients with intolerance to conventional therapy. Moreover, r",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33484058",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "a disorder characterized by hypercytokinemia in the setting of unbridled immune activation, and emapalumab represents the first therapeutic developed to address the underlying pathophysiology of HLH. Emapal",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31537529",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ember 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. Emapalumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30623346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "use of emapalumab for treatment of pHLH patients with refractory, recurrent or progressive disease, or intolerance to conventional therapy, recently, leading to FDA approval of the drug for these indications. Additional data are needed to",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33424859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab is approved for treatment of primary HLH that is refractory, recurrent, progressing or intolerant to current HLH treatments in both adult and pediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The novel agent, emapalumab (an anti-IFN-\u03b3 monoclonal antibody) can be used to treat EBV-HLH cases to avoid the risk of secondary malignancy due to etoposide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34096649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hogenic role. Emapalumab, a monoclonal antibody directed against IFN-\u03b3, is the first target therapy approved for primary HLH with refractory, recurrent or progressive disease or intolerance to conventional therapy.AREAS COVERED: We reviewed the pharmacological characteristics, safety, efficacy and",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emapalumab is being developed by Novimmune and Swedish Orphan Biovitrum for the treatment of haemophagocytic lymphohistiocytosis (HLH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30623346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In November 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30623346",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "primary hemophagocytic lymphohistiocytosis"
}